Drug Trial Radar · NCT05767866
Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR
Last checked: Nov 19, 2026Latest source record: Mar 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
160
Planned (sponsor's estimate)
Start
Mar 30, 2018
Primary completion
Dec 30, 2023
Study completion May 30, 2024
Sponsor
- Lead sponsor
- Suzhou Puhe Pharmaceutical Technology Co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Mar 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aimed to evaluate the safety and preliminary efficacy of YK-029A, a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in treated or untreated patients with advanced non-small cell lung cancer (NSCLC).
Conditions
- Treatment
- Treatment Side Effects
Interventions
YK-029ADrug
Daily dose of YK-029A
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants that Experience Adverse Events (AEs) and Serious Adverse Events (SAEs) .Time frame: Cycle 1 (Cycle length is equal to [=] 28 days)
- Part 1: Number of Participants with Clinically Significant Abnormal Laboratory Values.Time frame: Cycle 1 (Cycle length is equal to [=] 28 days)
- Part 1: Number of Participants with First Cycle Dose-Limiting Toxicities (DLTs).Time frame: Cycle 1 (Cycle length is equal to [=] 28 days)
- Part 1: DLTs of Orally Administered YK-029A.Time frame: Cycle 1 (Cycle length is equal to [=] 28 days)
- Part 1: Number of Participants with First Cycle Dose-Limiting Toxicities (DLTs).Time frame: Cycle 1 (Cycle length is equal to [=] 28 days)
- Part 1: Maximum Tolerated Dose (MTD) of Orally Administered YK-029ATime frame: Cycle 1 (Cycle length is equal to [=] 28 days)
- Part 2: Objective Response Rate (ORR) according to RECIST 1.1 by IRCTime frame: Up to 36 months after first dose
- Part 3: Objective Response Rate (ORR) according to RECIST 1.1 by IRCTime frame: Up to 36 months after first dose
Locations
35 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, China · Recruiting
Beijing Chest Hospital Affiliated to Capital Medical University
Beijing, China · Recruiting
Beijing Hospital
Beijing, China · Recruiting
Beijing Tiantan Hospital affiliated to Capital Medical University
Beijing, China · Recruiting
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China · Recruiting
Peking University Cancer Hospital
Beijing, China · Recruiting
The Fifth Medical Center of the Chinese People's Liberation Army General Hospital
Beijing, China · Recruiting
Anhui Provincial Cancer Hospital
Hefei, Anhui, China · Recruiting
Anhui Provincial Hospital
Hefei, Anhui, China · Recruiting
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China · Recruiting
People's Hospital of Guangxi Zhuang Autonomous Region
Nanjing, Guangxi, China · Recruiting
Affiliated Tumor Hospital of Guangxi Medical University
Nanning, Guangxi, China · Recruiting
Affiliated Cancer Hospital of Harbin Medical University
Harbin, Heilongjiang, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhenzhou, Henan, China · Recruiting
Renmin Hospital of Wuhan University
Wuhan, Hubei, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Xiangya Hospital Central South University
Changsha, Hunan, China · Recruiting
Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University
Nanjin, Jiangsu, China · Recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Recruiting
Nanjing Chest Hospital
Nanjing, Jiangsu, China · Recruiting
Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China · Recruiting
Xuzhou Central Hospital
Xuzhou, Jiangsu, China · Recruiting
First Hospital of Jilin University
Changchun, Jilin, China · Recruiting
Jilin Tumor Hospital
Changchun, Jilin, China · Recruiting
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, China · Recruiting
Shengjing Hospital Affiliated to China Medical University
Shenyang, Liaoning, China · Recruiting
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Shanxi Cancer Hospital
Taiyuan, Shanxi, China · Recruiting
the First Affiliated Hospital; Medical College of Xi'an Jiaotong University
Xi’an, Shanxi, China · Recruiting
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Cancer in Zhejiang Province
Hangzhou, Zhejiang, China · Recruiting
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.